Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 30-Sep-24 4:32 PM View:  | Dowden Nathan J President & COO | Entrada Therapeutics, Inc. (TRDA) | 26-Sep-24 | Private Sale (Planned) | 847 | $16.00 | $13,552.00 | (< 1%) 126.0K to 125.15K | |
| 10-Sep-24 4:32 PM View: | Sethuraman Natarajan Chief Scientific Officer | Entrada Therapeutics, Inc. (TRDA) | 09-Sep-24 | Sale (Planned) | 2,642 | $15.09 | $39,862.20 | (1%) 186.46K to 183.82K | |
| 10-Sep-24 4:34 PM View: | Wentworth Kory James Chief Financial Officer | Entrada Therapeutics, Inc. (TRDA) | 09-Sep-24 | Private Sale (Planned) | 3,195 | $14.97 | $47,832.30 | (4%) 79.68K to 76.49K | |
| 10-Sep-24 4:33 PM View: | Dowden Nathan J President & COO | Entrada Therapeutics, Inc. (TRDA) | 09-Sep-24 | Sale (Planned) | 1,904 | $15.07 | $28,690.20 | (1%) 127.9K to 126.0K | |
| 10-Sep-24 4:32 PM View: | Sethuraman Natarajan Chief Scientific Officer | Entrada Therapeutics, Inc. (TRDA) | 06-Sep-24 | Private Sale (Planned) | 600 | $15.24 | $9,141.36 | (< 1%) 187.06K to 186.46K | |
| 10-Sep-24 4:33 PM View: | Dowden Nathan J President & COO | Entrada Therapeutics, Inc. (TRDA) | 06-Sep-24 | Private Sale (Planned) | 399 | $15.19 | $6,062.69 | (< 1%) 128.3K to 127.9K | |
| 05-Sep-24 6:46 PM View: | Wentworth Kory James Chief Financial Officer | Entrada Therapeutics, Inc. (TRDA) | 05-Sep-24 | Payment of Exercise | 165 | $15.13 | $2,495.79 | (< 1%) 79.85K to 79.68K | |
| 05-Sep-24 6:49 PM View: | Doshi Dipal CEO Director | Entrada Therapeutics, Inc. (TRDA) | 05-Sep-24 | Payment of Exercise | 826 | $15.13 | $12,494.10 | (< 1%) 326.58K to 325.75K | |
| 05-Sep-24 6:47 PM View: | Sethuraman Natarajan Chief Scientific Officer | Entrada Therapeutics, Inc. (TRDA) | 05-Sep-24 | Payment of Exercise | 167 | $15.13 | $2,526.04 | (< 1%) 187.22K to 187.06K | |
| 05-Sep-24 6:48 PM View: | Dowden Nathan J President & COO | Entrada Therapeutics, Inc. (TRDA) | 05-Sep-24 | Payment of Exercise | 171 | $15.13 | $2,586.55 | (< 1%) 128.47K to 128.3K | |
| 05-Sep-24 6:49 PM View: | Doshi Dipal CEO Director | Entrada Therapeutics, Inc. (TRDA) | 04-Sep-24 | Payment of Exercise | 4,744 | $15.42 | $73,168.60 | (1%) 331.32K to 326.58K | |
| 05-Sep-24 6:47 PM View: | Sethuraman Natarajan Chief Scientific Officer | Entrada Therapeutics, Inc. (TRDA) | 04-Sep-24 | Payment of Exercise | 955 | $15.42 | $14,729.30 | (< 1%) 188.18K to 187.22K | |
| 05-Sep-24 6:48 PM View: | Dowden Nathan J President & COO | Entrada Therapeutics, Inc. (TRDA) | 04-Sep-24 | Payment of Exercise | 983 | $15.42 | $15,161.20 | (< 1%) 129.45K to 128.47K | |
| 05-Sep-24 6:46 PM View: | Wentworth Kory James Chief Financial Officer | Entrada Therapeutics, Inc. (TRDA) | 04-Sep-24 | Payment of Exercise | 941 | $15.42 | $14,513.40 | (1%) 80.79K to 79.85K | |
| 05-Sep-24 6:48 PM View: | Dowden Nathan J President & COO | Entrada Therapeutics, Inc. (TRDA) | 03-Sep-24 | Payment of Exercise | 654 | $16.08 | $10,518.50 | (< 1%) 130.11K to 129.45K | |
| 05-Sep-24 6:46 PM View: | Wentworth Kory James Chief Financial Officer | Entrada Therapeutics, Inc. (TRDA) | 03-Sep-24 | Payment of Exercise | 625 | $16.08 | $10,051.40 | (< 1%) 81.41K to 80.79K | |
| 05-Sep-24 6:49 PM View: | Doshi Dipal CEO Director | Entrada Therapeutics, Inc. (TRDA) | 03-Sep-24 | Payment of Exercise | 3,152 | $16.08 | $50,694.40 | (< 1%) 334.48K to 331.32K | |
| 05-Sep-24 6:47 PM View: | Sethuraman Natarajan Chief Scientific Officer | Entrada Therapeutics, Inc. (TRDA) | 03-Sep-24 | Payment of Exercise | 634 | $16.08 | $10,195.50 | (< 1%) 188.81K to 188.18K | |
| 20-Aug-24 4:33 PM View: | Dowden Nathan J President & COO | Entrada Therapeutics, Inc. (TRDA) | 16-Aug-24 | Option Exercise | 20,000 | $1.74 | $34,800.00 | 15% 137.2K to 157.2K | |
| 20-Aug-24 4:33 PM View: | Dowden Nathan J President & COO | Entrada Therapeutics, Inc. (TRDA) | 16-Aug-24 | Planned Option Sale | 20,000 | $16.27 | $325,350.00 | (13%) 157.2K to 137.2K | |
| 20-Aug-24 4:33 PM View: | Dowden Nathan J President & COO | Entrada Therapeutics, Inc. (TRDA) | 16-Aug-24 | Sale (Planned) | 7,097 | $16.27 | $115,451.00 | (5%) 137.2K to 130.11K | |
| 16-Jul-24 4:42 PM View: | Doshi Dipal CEO Director | Entrada Therapeutics, Inc. (TRDA) | 15-Jul-24 | Sale (Planned) | 1,600 | $17.81 | $28,497.30 | (< 1%) 336.07K to 334.48K | |
| 16-Jul-24 4:43 PM View: | Sethuraman Natarajan Chief Scientific Officer | Entrada Therapeutics, Inc. (TRDA) | 15-Jul-24 | Sale (Planned) | 638 | $18.00 | $11,484.00 | (< 1%) 189.45K to 188.81K | |
| 16-Jul-24 4:42 PM View: | Doshi Dipal CEO Director | Entrada Therapeutics, Inc. (TRDA) | 12-Jul-24 | Private Sale (Planned) | 300 | $18.00 | $5,400.00 | (< 1%) 336.38K to 336.07K | |
| 16-Jul-24 4:43 PM View: | Sethuraman Natarajan Chief Scientific Officer | Entrada Therapeutics, Inc. (TRDA) | 12-Jul-24 | Private Sale (Planned) | 600 | $18.00 | $10,800.00 | (< 1%) 190.05K to 189.45K | |
| 10-Jul-24 4:34 PM View: | Wentworth Kory James Chief Financial Officer | Entrada Therapeutics, Inc. (TRDA) | 08-Jul-24 | Private Sale (Planned) | 1,758 | $14.95 | $26,282.10 | (2%) 83.17K to 81.41K | |
| 14-Jun-24 4:32 PM View: | Doshi Dipal CEO Director | Entrada Therapeutics, Inc. (TRDA) | 13-Jun-24 | Private Sale (Planned) | 1,000 | $16.17 | $16,173.60 | (< 1%) 337.38K to 336.38K | |
| 05-Jun-24 4:31 PM View: | Kim Peter S Director | Entrada Therapeutics, Inc. (TRDA) | 03-Jun-24 | Option Exercise | 11,918 | $6.06 | $72,223.10 | 13% 92.41K to 104.33K | |
| 20-May-24 5:26 PM View: | Sethuraman Natarajan Chief Scientific Officer | Entrada Therapeutics, Inc. (TRDA) | 20-May-24 | Sale (Planned) | 9,675 | $15.19 | $146,944.00 | (5%) 199.73K to 190.05K | |
| 20-May-24 5:21 PM View: | Doshi Dipal CEO Director | Entrada Therapeutics, Inc. (TRDA) | 17-May-24 | Sale (Planned) | 1,200 | $15.11 | $18,129.10 | (< 1%) 338.57K to 337.38K | |
| 20-May-24 5:26 PM View: | Sethuraman Natarajan Chief Scientific Officer | Entrada Therapeutics, Inc. (TRDA) | 17-May-24 | Sale (Planned) | 8,305 | $15.14 | $125,751.00 | (4%) 208.03K to 199.73K | |
| 20-May-24 5:21 PM View: | Doshi Dipal CEO Director | Entrada Therapeutics, Inc. (TRDA) | 16-May-24 | Private Sale (Planned) | 1,800 | $15.00 | $27,000.00 | (< 1%) 340.38K to 338.57K | |
| 20-May-24 5:26 PM View: | Sethuraman Natarajan Chief Scientific Officer | Entrada Therapeutics, Inc. (TRDA) | 16-May-24 | Private Sale (Planned) | 1,000 | $15.00 | $15,000.00 | (< 1%) 209.03K to 208.03K | |
| 16-May-24 4:33 PM View: | Kim Peter S Director | Entrada Therapeutics, Inc. (TRDA) | 14-May-24 | Purchase | 25,000 | $14.59 | $364,672.00 | 37% 67.41K to 92.41K | |
| 10-May-24 4:35 PM View: | Kim Peter S Director | Entrada Therapeutics, Inc. (TRDA) | 09-May-24 | Purchase | 2,200 | $14.25 | $31,341.00 | 3% 65.21K to 67.41K | |
| 10-May-24 4:35 PM View: | Kim Peter S Director | Entrada Therapeutics, Inc. (TRDA) | 08-May-24 | Purchase | 2,276 | $14.04 | $31,964.60 | 4% 62.94K to 65.21K | |
| 10-Apr-24 4:35 PM View: | Kim Peter S Director | Entrada Therapeutics, Inc. (TRDA) | 08-Apr-24 | Purchase | 2,600 | $13.57 | $35,289.80 | 4% 60.34K to 62.94K | |
| 01-Apr-24 4:31 PM View: | Kim Peter S Director | Entrada Therapeutics, Inc. (TRDA) | 28-Mar-24 | Purchase | 1,512 | $13.75 | $20,793.90 | 3% 58.82K to 60.34K | |
| 26-Mar-24 5:57 PM View: | Kim Peter S Director | Entrada Therapeutics, Inc. (TRDA) | 26-Mar-24 | Purchase | 2,750 | $13.64 | $37,509.20 | 5% 56.07K to 58.82K | |
| 26-Mar-24 5:57 PM View: | Kim Peter S Director | Entrada Therapeutics, Inc. (TRDA) | 25-Mar-24 | Purchase | 3,180 | $13.36 | $42,472.10 | 6% 52.89K to 56.07K | |
| 26-Mar-24 5:57 PM View: | Kim Peter S Director | Entrada Therapeutics, Inc. (TRDA) | 22-Mar-24 | Purchase | 3,118 | $13.76 | $42,900.60 | 6% 49.78K to 52.89K | |
| 21-Mar-24 4:31 PM View: | Kim Peter S Director | Entrada Therapeutics, Inc. (TRDA) | 21-Mar-24 | Purchase | 704 | $13.24 | $9,317.65 | 1% 49.07K to 49.78K | |
| 21-Mar-24 4:31 PM View: | Kim Peter S Director | Entrada Therapeutics, Inc. (TRDA) | 20-Mar-24 | Market Purchase | 1,128 | $12.66 | $14,280.90 | 2% 47.94K to 49.07K | (11%) |
| 21-Mar-24 4:31 PM View: | Kim Peter S Director | Entrada Therapeutics, Inc. (TRDA) | 19-Mar-24 | Market Purchase | 900 | $12.66 | $11,397.00 | 2% 47.04K to 47.94K | (11%) |
| 19-Mar-24 4:33 PM View: | Wentworth Kory James Chief Financial Officer | Entrada Therapeutics, Inc. (TRDA) | 15-Mar-24 | Option Exercise | 9,000 | $2.10 | $18,900.00 | 12% 74.17K to 83.17K | |
| 08-Mar-24 4:36 PM View: | Wentworth Kory James Chief Financial Officer | Entrada Therapeutics, Inc. (TRDA) | 06-Mar-24 | Private Sale (Planned) | 4,086 | $12.31 | $50,285.20 | (5%) 78.26K to 74.17K | |
| 08-Mar-24 4:34 PM View: | Dowden Nathan J President & COO | Entrada Therapeutics, Inc. (TRDA) | 06-Mar-24 | Private Sale (Planned) | 1,826 | $12.32 | $22,498.70 | (1%) 139.03K to 137.2K | |
| 05-Mar-24 7:47 PM View: | Wentworth Kory James Chief Financial Officer | Entrada Therapeutics, Inc. (TRDA) | 05-Mar-24 | Payment of Exercise | 1,471 | $12.28 | $18,062.10 | (2%) 79.73K to 78.26K | |
| 05-Mar-24 7:48 PM View: | Doshi Dipal CEO Director | Entrada Therapeutics, Inc. (TRDA) | 05-Mar-24 | Payment of Exercise | 5,049 | $12.28 | $61,995.70 | (1%) 345.42K to 340.38K | |
| 05-Mar-24 7:46 PM View: | Dowden Nathan J President & COO | Entrada Therapeutics, Inc. (TRDA) | 05-Mar-24 | Payment of Exercise | 1,486 | $12.28 | $18,246.30 | (1%) 140.52K to 139.03K |
